What's New

Last Posted: Oct 05, 2024

• Genomic Landscape of Myelodysplastic/Myeloproliferative Neoplasms: A Multi-Central Study.
  Fei Fei, et al. International journal of molecular sciences 2024 0 (18)
• PHF6 mutations in chronic myelomonocytic leukemia identify a unique subset of patients with distinct phenotype and superior prognosis.
  Ayalew Tefferi, et al. American journal of hematology 2024 0
• Impact of spliceosome mutation on outcomes of myelodysplastic syndrome and chronic myelomonocytic leukemia patients undergoing allogeneic hematopoietic cell transplantation.
  Amrita Desai, et al. Leukemia research 2024 0 107565
• Utility of KIT Mutations in Myeloid Neoplasms Without Documented Systemic Mastocytosis to Detect Hidden Mast Cells in Bone Marrow.
  Do Hwan Kim, et al. Clinical lymphoma, myeloma & leukemia 2024 0
• ASXL1/TET2 genotype-based risk stratification outperforms ASXL1 mutational impact and is independent of mutant variant allele fractions in chronic myelomonocytic leukemia.
  Clifford M Csizmar, et al. Haematologica 2024 0
• Analysis of CSF3R mutations in atypical chronic myeloid leukemia and other myeloid malignancies.
  Seon Young Kim, et al. Annals of diagnostic pathology 2024 0 152317
• A novel 3q interstitial deletion including GATA2 and ZNF148: A case report.
  Elizabeth Martin, et al. American journal of medical genetics. Part A 2024 0 e63621
• NLRP3 inflammasome activation and symptom burden in KRAS-mutated CMML patients is reverted by IL-1 blocking therapy.
  Laura Hurtado-Navarro, et al. Cell reports. Medicine 2023 0 (12) 101329
• Germline CSF3R Variant in Chronic Myelomonocytic Leukemia: Linking Genetic Predisposition to Uncommon Hemorrhagic Symptoms.
  Maria Teresa Bochicchio, et al. International journal of molecular sciences 2023 0 (22)
• Impact of BRAF mutation on aggressiveness and outcomes in adult clonal histiocytosis.
  Jerome Razanamahery, et al. Frontiers in immunology 2023 0 1260193
• Characteristics and clinical outcomes of patients with myeloid malignancies and DDX41 variants.
  Alex Bataller, et al. American journal of hematology 2023 0
• Sex-associated differences in genomic profile of chronic myelomonocytic leukemia involving differential representation of SRSF2 gene mutation.
  Xavier Calvo, et al. International journal of laboratory hematology 2023 0
• DNA methylation profile in chronic myelomonocytic leukemia associates with distinct clinical, biological and genetic features.
  Palomo Laura, et al. Epigenetics 2017 0 (1) 8-18
• Therapy related-chronic myelomonocytic leukemia (CMML): Molecular, cytogenetic, and clinical distinctions from de novo CMML.
  Patnaik Mrinal M, et al. American journal of hematology 2017 0 (1) 65-73
• Utility of JAK2 V617F allelic burden in distinguishing chronic myelomonocytic Leukemia from Primary myelofibrosis with monocytosis.
  Hu Zhihong, et al. Human pathology 2018 0 290-298
• Mutation analysis of therapy-related myeloid neoplasms.
  Nishiyama Takahiro, et al. Cancer genetics 2018 0 38-45
• Clinical, molecular, and prognostic correlates of number, type, and functional localization of TET2 mutations in chronic myelomonocytic leukemia (CMML)-a study of 1084 patients.
  Coltro Giacomo, et al. Leukemia 2019 0 (5) 1407-1421
• Genotypic and phenotypic evolution in a patient with chronic myelomonocytic leukemia.
  Geissler Klaus, et al. Leukemia research reports 2019 0 100185
• Impact of clinical, cytogenetic, and molecular profiles on long-term survival after transplantation in patients with chronic myelomonocytic leukemia.
  Woo Janghee, et al. Haematologica 2019 0 (3) 652-660
• DDX41 mutations in myeloid neoplasms are associated with male gender, TP53 mutations and high-risk disease.
  Quesada Andrés E, et al. American journal of hematology 2019 0 (7) 757-766
• Invariant phenotype and molecular association of biallelic TET2 mutant myeloid neoplasia.
  Awada Hassan, et al. Blood advances 2019 0 (3) 339-349
• Clinical outcomes and influence of mutation clonal dominance in oligomonocytic and classical chronic myelomonocytic leukemia.
  Montalban-Bravo Guillermo, et al. American journal of hematology 2020 0 (2) E50-E53
• Cytogenetic and molecular landscape and its potential clinical significance in Hispanic CMML patients from Puerto Rico.
  Jiang Zeju, et al. Oncotarget 2020 0 (47) 4411-4420
• Clinical, Hematologic, Biologic and Molecular Characteristics of Patients with Myeloproliferative Neoplasms and a Chronic Myelomonocytic Leukemia-Like Phenotype.
  Heibl Sonja, et al. Cancers 2020 0 (7)
• Juvenile myelomonocytic leukemia - A bona fide RASopathy syndrome.
  Lasho Terra, et al. Best practice & research. Clinical haematology 2020 0 (2) 101171
• Molecular landscape and clonal architecture of adult myelodysplastic/myeloproliferative neoplasms.
  Palomo Laura, et al. Blood 2020 0 (16) 1851-1862
• Role of lncRNA Morrbid in PTPN11(Shp2)E76K-driven juvenile myelomonocytic leukemia.
  Cai Zhigang, et al. Blood advances 2020 0 (14) 3246-3251
• A novel intensive conditioning regimen for allogeneic hematopoietic stem cell transplantation in the treatment of relapsed/refractory acute myeloid leukemia.
  Sun Yanling, et al. Neoplasma 2021 0 (6) 1351-1358
• Looking for somatic mutations in UBA1 in patients with chronic myelomonocytic leukemia associated with systemic inflammation and autoimmune diseases.
  Dupuy Henry, et al. Leukemia & lymphoma 2021 0 (1) 250-252
• Mutational landscape of chronic myelomonocytic leukemia and its potential clinical significance.
  Han Wenmin, et al. International journal of hematology 2021 0 (1) 21-32
• Mutational profile and relative telomere length in Chronic Myelomonocytic Leukemia subgroups according to the 2016 World Health Organization classification.
  Martinez-Verbo Laura, et al. Leukemia research 2021 0 106726
• Myeloid Clonal Infiltrate Identified With Next-Generation Sequencing in Skin Lesions Associated With Myelodysplastic Syndromes and Chronic Myelomonocytic Leukemia: A Case Series.
  Martin de Frémont Grégoire, et al. Frontiers in immunology 2021 0 715053
• Durable Response to Crizotinib in a Patient with Pulmonary Adenocarcinoma Harboring MET Intron 14 Mutation: A Case Report.
  Leyrat Brice, et al. OncoTargets and therapy 2021 0 3949-3958
• Mutations in chronic myelomonocytic leukemia and their prognostic relevance.
  Jian J, et al. Clinical & translational oncology : official publication of the Federation of Spanish Oncology Societies and of the National Cancer Institute of Mexico 2021 0 (9) 1731-1742
• A prognostic score including mutation profile and clinical features for patients with CMML undergoing stem cell transplantation.
  Gagelmann Nico, et al. Blood advances 2021 0 (6) 1760-1769
• Significance of cardiovascular comorbidity in patients with chronic myelomonocytic leukemia.
  Lackner David, et al. Wiener medizinische Wochenschrift (1946) 2022 0 (1-2) 27-33
• Significance of hypergammaglobulinemia in patients with chronic myelomonocytic leukemia.
  Zack Marie-Therese, et al. Wiener medizinische Wochenschrift (1946) 2022 0 (1-2) 21-26
• Outcomes and molecular profile of oligomonocytic CMML support its consideration as the first stage in the CMML continuum.
  Calvo Xavier, et al. Blood advances 2022 0 (13) 3921-3931
• A case of refractory systemic lupus erythematosus with monocytosis exhibiting somatic KRAS mutation.
  Law Sze-Ming, et al. Inflammation and regeneration 2022 0 (1) 10
• Coexistence of Chronic Myelomonocytic Leukemia and Ulcerative Colitis With Rapid Progression to Acute Myelomonocytic Leukemia: A Case Report.
  Pelkey Lauren J, et al. Cureus 2022 0 (2) e22422
• Monocytosis and its association with clonal hematopoiesis in community-dwelling individuals.
  van Zeventer Isabelle A, et al. Blood advances 2022 0 (14) 4174-4184
• Multistep pathogenesis of chronic myelomonocytic leukemia in patients.
  Geissler Klaus, et al. European journal of haematology 2022 0 (1) 50-57
• Outcomes following venetoclax-based treatment in therapy-related myeloid neoplasms.
  Shah Mithun Vinod, et al. American journal of hematology 2022 0 (8) 1013-1022
• Clinical correlates, prognostic impact and survival outcomes in chronic myelomonocytic leukemia patients with the JAK2V617F mutation.
  Patnaik Mrinal M, et al. Haematologica 2019 0 (6) e236-e239
• RAS, FLT3, and TP53 mutations in therapy-related myeloid malignancies with abnormalities of chromosomes 5 and 7.
  Side Lucy E, et al. Genes, chromosomes & cancer 2004 0 (3) 217-23
• The prognostic significance of bone marrow levels of neurofibromatosis-1 protein and ras oncogene mutations in patients with acute myeloid leukemia and myelodysplastic syndrome.
  Lu Di, et al. Cancer 2003 0 (2) 441-9
• Chronic myelomonocytic leukemia: 2022 update on diagnosis, risk stratification, and management.
  Patnaik Mrinal M, et al. American journal of hematology 2022 0 (3) 352-372
• Treatment options and survival in real life during the past three decades in patients with chronic myelomonocytic leukemia.
  Reiser Julia, et al. Wiener medizinische Wochenschrift (1946) 2022 10
• Genetics and clinical phenotype of Erdheim-Chester disease: A case report of constrictive pericarditis and a systematic review of the literature.
  Bartoli Lorenzo, et al. Frontiers in cardiovascular medicine 2022 0 876294
• SF3B1, RUNX1 and TP53 Mutations Significantly Impact the Outcome of Patients With Lower-Risk Myelodysplastic Syndrome.
  Falantes Jose F, et al. Clinical lymphoma, myeloma & leukemia 2022 8
• The Prognostic Ability of RAS Pathway-Related Gene Mutations in Patients with Myeloid Neoplasms Treated with Hypomethylating Agents.
  Park Hee Sue, et al. Acta haematologica 2021 7 1-11
• Myelomonocytic skewing in chronic myelomonocytic leukemia: phenotypic, molecular and biologic features and impact on survival.
  Geissler Klaus, et al. European journal of haematology 2021 1
• Correlation of RAS-Pathway Mutations and Spontaneous Myeloid Colony Growth with Progression and Transformation in Chronic Myelomonocytic Leukemia-A Retrospective Analysis in 337 Patients.
  Geissler Klaus, et al. International journal of molecular sciences 2020 4 (8)
• The Austrian biodatabase for chronic myelomonocytic leukemia (ABCMML) : A representative and useful real-life data source for further biomedical research.
  Geissler Klaus et al. Wiener klinische Wochenschrift 2019 Sep 131(17-18) 410-418
• Targeted sequencing aids in identifying clonality in chronic myelomonocytic leukemia.
  Hwang Sang Mee, et al. Leukemia research 2019 7 106190
• Myeloid malignancies with isolated 7q deletion can be further characterized by their accompanying molecular mutations.
  Hartmann Luise, et al. Genes, chromosomes & cancer 2019 4
• Local Coverage Determination (LCD): Genomic Sequence Analysis Panels in the Treatment of Hematolymphoid Diseases (L37606)
  The U.S. Centers for Medicare & Medicaid Services
• Poor Prognostic Implication of ASXL1 Mutations in Korean Patients With Chronic Myelomonocytic Leukemia.
  Kim Hyun Young, et al. Annals of laboratory medicine 2018 11 (6) 495-502
• Prognostic significance of SRSF2 mutations in myelodysplastic syndromes and chronic myelomonocytic leukemia: a meta-analysis.
  Arbab Jafari Pourya, et al. Hematology (Amsterdam, Netherlands) 2018 5 1-7
• Prognostic Role of Gene Mutations in Chronic Myelomonocytic Leukemia Patients Treated With Hypomethylating Agents.
  Duchmann Matthieu, et al. EBioMedicine 2018 4

More